X

Trial Profile

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Adverse reactions
Acronyms NiraRad

Most Recent Events

16 Nov 2022 Status changed from active, no longer recruiting to completed.
02 Nov 2022 Results assessing safety of niraparib in combination with Radium-223 for the treatment of metastatic castrate resistant prostate cancer in men without known BRCA mutations published in the Clinical Cancer Research
07 Sep 2022 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com